Table 2.

Characteristics of SOS/VOD patients.

Patient	Gender	Age	HSCT Type	Conditioning Regimen	Underlying Disease	Baseline 2D-SWE (m/S)	Baseline 2D-SWE (kPa)	Baseline PV Velocity (cm/S)	Clinical SOS/VOD Diagnosis †	Serum Bilirubin >2 mg/dL at Diagnosis	SWE at SOS/VOD Diagnosis (m/S)	SWE at SOS/VOD Diagnosis (kPa)	Max. Increase in SWE (m/S; kPa)	Max. SWE (m/S; kPa)	Ascites in US	Decreased/Reversed PV Flow	Gallbladder Wall Thickening	Date of US/SWE	SOS/VOD Severity †	Max. Bilirubin (mg/dL)	SOS/VOD Therapy	Outcome	SWD ((m/S)/kHz); (day)
1	male	36	allogenic (MMUD)	4 × 3.2 mg/kg busulfan, 2 × 60 mg/kg cyclophosphamide	AML	1.42	5.9	29	+18	3.26	4.17	58.8	2.75; 52.9	4.17; 58.8	yes ‡	yes	yes	+18	severe	34.71	DEF, diuretics	Death (+110)	16.7 (+20)
2	female	64	allogenic (MUD)	treosulfan, fludarabine, thiothepa	MM	1.26	4.7	29	+18	5.62	1.71	8.9	0.52; 5	1.78; 9.8	no	no	no	+19	severe	20.76	DEF, diuretics	death (+63)	17.2 (+54)
3	male	45	allogenic (MUD)	4 × 3.2 mg/kg busulfan, 2 × 60 mg/kg cyclophosphamide	CML	1.20	4.2	16	+21	4.46	2.11	13.9	2.52; 41.3	3.72; 45.5	yes ‡	yes	yes	+47	severe	35.83	DEF, diuretics	death (+78)	20.9 (+47)

Abbreviations: MUD, matched unrelated donor; MMUD, mismatch unrelated donor; AML, acute myeloid leukemia; MM, multiple myeloma; PV, portal vein; † according to Mohty et al. 2016 [7]; US, ultrasound; DEF, defibrotide; SWE, shear wave elastography; SWD, shear wave dispersion. ‡ Small amounts of ascites, no detection of ascites in the area of 2D-SWE measurement.